CytoSorbents (NASDAQ:CTSO) shareholders approved a reverse stock split authorization and re-elected the company’s five directors at its 2026 annual meeting, as management outlined a plan to reach operating cash flow breakeven in the second half of the year, restore growth in its core business and advance U.S. regulatory pathways for DrugSorb-ATR. Christopher J. Woods, vice […]